[Skip to Content]
[Skip to Content Landing]
March 1997

Ocular Myasthenia Gravis-Reply

Author Affiliations

New York University 530 First Ave Suite 3B New York, NY 10016

Arch Neurol. 1997;54(3):229. doi:10.1001/archneur.1997.00550150005002

In reply  I thank McQuillen for reminding me of the study report by Mount.1 This prospective treatment trial using 8 days of corticotropin appeared not to show any benefit on the abnormal ocular or lid function in patients with ocular myasthenia. Despite the fact that it was prospective, there were some significant flaws in the study. Most important was the lack of follow-up of the patients once it was felt that there was no real benefit to the medication. There-fore, patients were not followed up on any regular basis after the first 3 months. The course of medication delivered was brief and of course there were no significant side effects. Other problems arose with the fact that although patients had ocular myasthenia, there were a number of patients entered who had the illness for a considerable period and had not had generalized myasthenia. Therefore, one could not extrapolate whether